ENDRA Life Sciences (NDRA) Cash & Equivalents (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Cash & Equivalents for 11 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 3.79% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 3.79% decrease from a year earlier, with the FY2025 full-year figure at $762365.0, down 76.39% from the prior year.
• Cash & Equivalents was $1.7 million for Q2 2026 at ENDRA Life Sciences, up from $356462.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $11.3 million in Q2 2022 and troughed at $356462.0 in Q1 2026.
• A 5-year average of $3.8 million and a median of $3.0 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 81.98% in 2025, down 83.27% in 2025.
• Over 5 years, Cash & Equivalents stood at $4.9 million in 2022, then slumped by 42.04% to $2.8 million in 2023, then climbed by 13.96% to $3.2 million in 2024, then tumbled by 76.39% to $762365.0 in 2025, then soared by 128.23% to $1.7 million in 2026.
• The last three Cash & Equivalents figures came in at $1.7 million (Q2 2026), $356462.0 (Q1 2026), and $762365.0 (Q4 2025), per Business Quant data.